Tenderwize
Retour à la recherche

Open-House Discount Agreement Filgrastim

Techniker Krankenkasse·Hamburg, Germany·Deadline Apr 30, 2028 · 613 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-08 - Filgrastim

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

No guaranteed volume or revenue; agreements are non-exclusive and competitors may also join.

Only pharmaceutical entrepreneurs with own marketing authorization can participate; local distributors without such sta...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Supply of Filgrastim medicinal products to German statutory health insurance funds (Techniker Krankenkasse, HEK, hkk) under discount agreements.
  • Contract term: max. 24 months from 01.05.2026 to 30.04.2028.
Afficher le résumé complet

Open-house procedure for discount agreements on the active substance Filgrastim (biologic) with German statutory health insurers. Contract conclusion possible at any time during the term (max. 24 months from 01.05.2026). No exclusivity, no individual negotiations. Eligibility is strictly limited to pharmaceutical entrepreneurs under § 4 Abs. 18 AMG with a valid marketing authorization for the offered medicinal products. The tender is not a public procurement under EU law but uses the TED form for transparency. No estimated value provided. No procurement documents analyzed.

Risques

No guaranteed volume or revenue; agreements are non-exclusive and competitors may also join.

Only pharmaceutical entrepreneurs with own marketing authorization can participate; local distributors without such sta...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Bidders must be pharmaceutical entrepreneurs (pharmazeutischer Unternehmer) per § 4 Abs. 18 AMG for the offered medicinal products.
  • Valid marketing authorization for the offered medicinal products according to § 21 Abs. 1 AMG (or equivalent right to market).
  • No grounds for revocation or suspension of authorization.

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria specified; any qualified supplier can join (open-house model).

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open-House Discount Agreement Filgrastim

Conclusion of discount agreements for Filgrastim under § 130a Abs. 8 SGB V. Open-house procedure with uniform conditions, no exclusivity. Performance nationwide (Germany).

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Apr 2026 - Apr 2028

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria specified; any qualified supplier can join (open-house model).

Date limite

Deadline Apr 30, 2028

Détails de la procédure

Date de publication
18 Mar 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
192805-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3